Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2009 1
2019 2
2020 2
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab for the treatment of unresectable pleural mesothelioma.
Hotta K, Fujimoto N, Kozuki T, Aoe K, Kiura K. Hotta K, et al. Expert Opin Biol Ther. 2020 Feb;20(2):109-114. doi: 10.1080/14712598.2020.1703945. Epub 2019 Dec 16. Expert Opin Biol Ther. 2020. PMID: 31825692 Review.
Introduction: Platinum-based chemotherapy is the current first-line standard therapy for unresectable malignant pleural mesothelioma (MPM). Recently, immune-checkpoint inhibitors (ICI) have been intensively investigated as treatment options for …
Introduction: Platinum-based chemotherapy is the current first-line standard therapy for unresectable malignant pleu …
Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
Garcia-Carbonero R, Paz-Ares L. Garcia-Carbonero R, et al. Eur J Surg Oncol. 2006 Aug;32(6):676-81. doi: 10.1016/j.ejso.2006.03.009. Epub 2006 Apr 17. Eur J Surg Oncol. 2006. PMID: 16616827 Review.
RESULTS: Pemetrexed in combination with cisplatin is the first treatment regimen that demonstrates a survival improvement in patients with unresectable malignant pleural mesothelioma. Data from uncontrolled studies suggest similar antineoplastic effica …
RESULTS: Pemetrexed in combination with cisplatin is the first treatment regimen that demonstrates a survival improvement in patients with …
Recent advances in the treatment of malignant pleural mesothelioma.
Ramalingam SS, Belani CP. Ramalingam SS, et al. J Thorac Oncol. 2008 Sep;3(9):1056-64. doi: 10.1097/JTO.0b013e3181834f66. J Thorac Oncol. 2008. PMID: 18758312 Free article. Review.
Malignant pleural mesothelioma clinically manifests after decades of initial exposure to etiologic agents, such as asbestos, and presents with nonspecific symptoms such as dyspnea, pain, or weight loss. ...The combination of cisplatin and pemetrexed, a novel …
Malignant pleural mesothelioma clinically manifests after decades of initial exposure to etiologic agents, such as asbe …
Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.
Wang Y, Pandey M, Ballo MT. Wang Y, et al. Oncologist. 2019 Dec;24(12):e1426-e1436. doi: 10.1634/theoncologist.2017-0603. Epub 2019 Aug 23. Oncologist. 2019. PMID: 31444292 Free PMC article. Review.
Human trials in patients with primary glioblastoma showed an improvement in overall survival, and trials in patients with unresectable malignant pleural mesothelioma showed favorable outcomes compared with historical control. ...TTFields will likely jo …
Human trials in patients with primary glioblastoma showed an improvement in overall survival, and trials in patients with unresectable …
Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.
Ye ZM, Tang ZQ, Xu Z, Zhou Q, Li H. Ye ZM, et al. Front Public Health. 2022 Jul 22;10:947375. doi: 10.3389/fpubh.2022.947375. eCollection 2022. Front Public Health. 2022. PMID: 35937220 Free PMC article.
BACKGROUND: The treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. ...CONCLUSIONS: The ICER of Nivolumab plus ipilimumab is above the theoretical willingness-to-pay threshold in the U.S, which suggests …
BACKGROUND: The treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent ye …
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y, Qosa H, Liu J, Zhao H, Biable M, Hotaki LT, Shen YL, Pazdur R, Beaver JA, Singh H, Donoghue M. Nakajima EC, et al. Clin Cancer Res. 2022 Feb 1;28(3):446-451. doi: 10.1158/1078-0432.CCR-21-1466. Epub 2021 Aug 30. Clin Cancer Res. 2022. PMID: 34462287 Free PMC article.
On October 2, 2020, FDA approved nivolumab with ipilimumab as first-line treatment for adult patients with unresectable malignant pleural mesothelioma (MPM). The approval was based on results from Study CA209743 (CHECKMATE-743), an open-label trial of …
On October 2, 2020, FDA approved nivolumab with ipilimumab as first-line treatment for adult patients with unresectable malignant …
Pemetrexed in first-line treatment of non-small cell lung cancer.
Esteban E, Casillas M, Cassinello A. Esteban E, et al. Cancer Treat Rev. 2009 Jun;35(4):364-73. doi: 10.1016/j.ctrv.2009.02.002. Epub 2009 Mar 6. Cancer Treat Rev. 2009. PMID: 19269106 Review.
Pemetrexed is an antitumor agent traditionally used as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) as well as in combination with cisplatin for the treatment of chemonaive patients with unresectab …
Pemetrexed is an antitumor agent traditionally used as monotherapy for the second-line treatment of patients with locally advanced or metast …
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
Green J, Dundar Y, Dodd S, Dickson R, Walley T. Green J, et al. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD005574. doi: 10.1002/14651858.CD005574.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253564 Free PMC article. Review.
Pemetrexed is the first and only chemotherapy agent that has been granted a marketing approval for use in combination with cisplatin for the treatment of chemo-naive patients with unresectable MPM. OBJECTIVES: To examine evidence on the clinical effectiveness of pemetrexed …
Pemetrexed is the first and only chemotherapy agent that has been granted a marketing approval for use in combination with cisplatin for the …
Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
Kitajima K, Maruyama M, Minami T, Yokoi T, Kuribayashi K, Kijima T, Hashimoto M, Hasegawa S, Yamakado K. Kitajima K, et al. Nucl Med Commun. 2020 Aug;41(8):790-799. doi: 10.1097/MNM.0000000000001223. Nucl Med Commun. 2020. PMID: 32516245
OBJECTIVE: To compare modified RECIST (mRECIST), EORTC criteria, and PERCIST for response evaluation and prognosis prediction in advanced malignant pleural mesothelioma (MPM) patients treated with chemotherapy. ...CONCLUSION: EORTC and PERCIST are more accura …
OBJECTIVE: To compare modified RECIST (mRECIST), EORTC criteria, and PERCIST for response evaluation and prognosis prediction in advanced …